camonsertib
AssetAlso RP-3500
Inhibits ATR kinase, disrupting DNA damage responses and promoting death of susceptible cancer cells.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 4
- Trials
- 1
- Developer
Indications
2Advanced solid tumor
Phase 1, Completed, NCT04497116, clinicaltrials.gov, Oct 31, 2026
Adult advanced solid tumor
Phase 1, Terminated, NCT04972110, clinicaltrials.gov, Oct 24, 2026
In the full profile
- Owner and partners1
- Trials4
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.